Immunotherapy for Head and Neck Squamous Cell Carcinoma

Hematology/Oncology Clinics of North America

Volumn 29, Issue 6, 2015, Pages 1033-1043

  Schoppy, David W ^a   Sunwoo, John B ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cetuximab; Chimeric antigen receptor; CTLA 4; HNSCC; Immunotherapy; PD 1; Vaccine

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CETUXIMAB; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY;

ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BIOLOGICAL THERAPY; CARCINOMA, SQUAMOUS CELL; DRUG EFFECTS; GENETICS; HEAD AND NECK NEOPLASMS; HUMAN; IMMUNE SYSTEM; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CARCINOMA, SQUAMOUS CELL; CELL- AND TISSUE-BASED THERAPY; CETUXIMAB; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTE SUBSETS;

EID: 85027955837     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2015.07.009     Document Type: Review

References (65)

1. Ho, A.S., Kraus, D.H., Ganly, I., et al. Decision making in the management of recurrent head and neck cancer. Head Neck 36 (2014), 144–151.
2. Vermorken, J.B., Specenier, P., Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol 21:Suppl 7 (2010), vii252–vii261.
3. Argiris, A., Karamouzis, M.V., Raben, D., et al. Head and neck cancer. Lancet 371 (2008), 1695–1709.
4. Galluzzi, L., Vacchelli, E., Bravo-San Pedro, J.M., et al. Classification of current anticancer immunotherapies. Oncotarget 5 (2014), 12472–12508.
5. Ehrlich, P., Uber den jetzigen Stand der Karzinomforschung. Ned Tijdschr Geneeskd 5 (1909), 273–290.
6. Manjili, M.H., Revisiting cancer immunoediting by understanding cancer immune complexity. J Pathol 224 (2011), 5–9.
7. Hodi, F.S., O'Day, S.J., McDermott, D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363 (2010), 711–723.
8. Ritprajak, P., Azuma, M., Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma. Oral Oncol 51 (2015), 221–228.
9. Topalian, S.L., Hodi, F.S., Brahmer, J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366 (2012), 2443–2454.
10. Brahmer, J.R., Tykodi, S.S., Chow, L.Q., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366 (2012), 2455–2465.
11. Robert, C., Ribas, A., Wolchok, J.D., et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 384 (2014), 1109–1117.
12. Robert, C., Long, G.V., Brady, B., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372 (2015), 320–330.
13. Garon, E.B., Rizvi, N.A., Hui, R., et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372 (2015), 2018–2028.
14. Brahmer, J., Reckamp, K.L., Baas, P., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:2 (2015), 123–135.
15. Strome, S.E., Dong, H., Tamura, H., et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res 63 (2003), 6501–6505.
16. Kim, H.S., et al. The prevalence and prognostic relevance of PD-L1 expression in patients with HPV-negative and HPV-positive oropharyngeal cancer. ASCO Meeting Abstracts, 33, 2015, e14003.
17. Seiwert, T.Y., et al. Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): preliminary results from KEYNOTE-012 expansion cohort. ASCO Meeting Abstracts, 33, 2015, LBA6008.
18. Segal, N.H., et al. Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort. ASCO Meeting Abstracts, 33, 2015, 3011.
19. Cohen, E.E.W., et al. KEYNOTE-040: a phase III randomized trial of pembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer. ASCO Meeting Abstracts, 33, 2015, TPS6084.
20. Tumeh, P.C., Harview, C.L., Yearley, J.H., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515 (2014), 568–571.
21. Powles, T., Eder, J.P., Fine, G.D., et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515 (2014), 558–562.
22. Herbst, R.S., Soria, J.C., Kowanetz, M., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515 (2014), 563–567.
23. Postow, M.A., Callahan, M.K., Barker, C.A., et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366 (2012), 925–931.
24. Twyman-Saint Victor, C., Rech, A.J., Maity, A., et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520:7547 (2015), 373–377.
25. Fu, J., Kanne, D.B., Leong, M., et al. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci Transl Med, 7, 2015, 283ra52.
26. Arteaga, C.L., Engelman, J.A., ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 25 (2014), 282–303.
27. Bauman, J.E., Ferris, R.L., Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer. Cancer 120 (2014), 624–632.
28. Bernier, J., Incorporation of molecularly targeted agents in the primary treatment of squamous cell carcinomas of the head and neck. Hematol Oncol Clin North Am 22 (2008), 1193–1208 ix.
29. Reeves, T.D., Hill, E.G., Armeson, K.E., et al. Cetuximab therapy for head and neck squamous cell carcinoma: a systematic review of the data. Otolaryngol Head Neck Surg 144 (2011), 676–684.
30. Bonner, J.A., Harari, P.M., Giralt, J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006), 567–578.
31. Vermorken, J.B., Mesia, R., Rivera, F., et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359 (2008), 1116–1127.
32. Ferris, R.L., Jaffee, E.M., Ferrone, S., Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol 28 (2010), 4390–4399.
33. Taylor, R.J., Saloura, V., Jain, A., et al. Ex vivo antibody-dependent cellular cytotoxicity inducibility predicts efficacy of cetuximab. Cancer Immunol Res 3 (2015), 567–574.
34. + cytolytic T cells and responsiveness to IL-2 but not cytolytic activity. J Immunol 169 (2002), 4230–4236.
35. Lin, W., Voskens, C.J., Zhang, X., et al. Fc-dependent expression of CD137 on human NK cells: insights into “agonistic” effects of anti-CD137 monoclonal antibodies. Blood 112 (2008), 699–707.
36. Kohrt, H.E., Colevas, A.D., Houot, R., et al. Targeting CD137 enhances the efficacy of cetuximab. J Clin Invest 124 (2014), 2668–2682.
37. Yang, X., Zhang, X., Mortenson, E.D., et al. Cetuximab-mediated tumor regression depends on innate and adaptive immune responses. Mol Ther 21 (2013), 91–100.
38. Srivastava, R.M., Lee, S.C., Andrade Filho, P.A., et al. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res 19 (2013), 1858–1872.
39. + T cells. Cancer Immunol Immunother 62 (2013), 1347–1357.
40. Jie, H.B., Schuler, P.J., Lee, S.C., et al. CTLA-4+ regulatory T cells are increased in cetuximab treated head and neck cancer patients, suppress NK cell cytotoxicity and correlate with poor prognosis. Cancer Res 75:11 (2015), 2200–2210.
41. Palucka, K., Banchereau, J., Dendritic-cell-based therapeutic cancer vaccines. Immunity 39 (2013), 38–48.
42. Li, Q., Prince, M.E., Moyer, J.S., Immunotherapy for head and neck squamous cell carcinoma. Oral Oncol 51 (2015), 299–304.
43. Leemans, C.R., Braakhuis, B.J., Brakenhoff, R.H., The molecular biology of head and neck cancer. Nat Rev Cancer 11 (2011), 9–22.
44. Albers, A., Abe, K., Hunt, J., et al. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck. Cancer Res 65 (2005), 11146–11155.
45. Gildener-Leapman, N., Lee, J., Ferris, R.L., Tailored immunotherapy for HPV positive head and neck squamous cell cancer. Oral Oncol 50 (2014), 780–784.
46. Voskens, C.J., Sewell, D., Hertzano, R., et al. Induction of MAGE-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma. Head Neck 34 (2012), 1734–1746.
47. Lin, K., Roosinovich, E., Ma, B., et al. Therapeutic HPV DNA vaccines. Immunol Res 47 (2010), 86–112.
48. Peng, S., Lyford-Pike, S., Akpeng, B., et al. Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine. Cancer Immunol Immunother 62 (2013), 171–182.
49. Poeta, M.L., Manola, J., Goldwasser, M.A., et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 357 (2007), 2552–2561.
50. Agrawal, N., Frederick, M.J., Pickering, C.R., et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333 (2011), 1154–1157.
51. Stransky, N., Egloff, A.M., Tward, A.D., et al. The mutational landscape of head and neck squamous cell carcinoma. Science 333 (2011), 1157–1160.
52. Hoffmann, T.K., Donnenberg, A.D., Finkelstein, S.D., et al. Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer. Cancer Res 62 (2002), 3521–3529.
53. Hoffmann, T.K., Nakano, K., Elder, E.M., et al. Generation of T cells specific for the wild-type sequence p53(264-272) peptide in cancer patients: implications for immunoselection of epitope loss variants. J Immunol 165 (2000), 5938–5944.
54. Schuler, P.J., Harasymczuk, M., Visus, C., et al. Phase I dendritic cell p53 peptide vaccine for head and neck cancer. Clin Cancer Res 20 (2014), 2433–2444.
55. Whiteside, T.L., Ferris, R.L., Szczepanski, M., et al. Dendritic cell-based autologous tumor vaccines for head and neck squamous cell carcinoma: promise vs reality. Head Neck, 2015 [Epub ahead of print].
56. Vonderheide, R.H., June, C.H., Engineering T cells for cancer: our synthetic future. Immunol Rev 257 (2014), 7–13.
57. June, C.H., Maus, M.V., Plesa, G., et al. Engineered T cells for cancer therapy. Cancer Immunol Immunother 63 (2014), 969–975.
58. Maus, M.V., June, C.H., CARTs on the road for myeloma. Clin Cancer Res 20 (2014), 3899–3901.
59. Barrett, D.M., Singh, N., Porter, D.L., et al. Chimeric antigen receptor therapy for cancer. Annu Rev Med 65 (2014), 333–347.
60. Maude, S.L., Frey, N., Shaw, P.A., et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371 (2014), 1507–1517.
61. Johnson, L.A., Scholler, J., Ohkuri, T., et al. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci Transl Med, 7, 2015, 275ra22.
62. Davies, D.M., Foster, J., Van Der Stegen, S.J., et al. Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells. Mol Med 18 (2012), 565–576.
63. van der Stegen, S.J., Davies, D.M., Wilkie, S., et al. Preclinical in vivo modeling of cytokine release syndrome induced by ErbB-retargeted human T cells: identifying a window of therapeutic opportunity?. J Immunol 191 (2013), 4589–4598.
64. van Schalkwyk, M.C., Papa, S.E., Jeannon, J.P., et al. Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer. Hum Gene Ther Clin Dev 24 (2013), 134–142.
65. Stevanovic, S., Draper, L.M., Langhan, M.M., et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol 33 (2015), 1543–1550.